NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

08/05/2026

1

Buy

$22.00

72.41%

Acadia Pharmaceuticals provided a March Q Daybue sales update, from which Neuren Pharmaceuticals receives royalties and milestones. Daybue sales were up 20% year on year and down -8% quarter on quarter, modestly below Acadia's US analyst consensus.

The 20% growth rate is a welcome uplift from the 11-14% growth in each of the last five quarters, Bell Potter notes. A key driver of the step up has been the launch of the new powder formulation, called Daybue Stix.

Neuren's biggest priority is quickly activating the 20-plus US clinical sites and enrolling the 160 patients for its Phase 3 trial of NNZ-2591 in Phelan McDermid syndrome, Bell Potter suggests. Buy and $22 target retained.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 4.80 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 5.20 cents.

21/05/2026

1

Buy

$24.00

88.09%

Canaccord Genuity retains a Buy rating for Neuren Pharmaceutical with an unchanged target price of $24.00 following a review of the upcoming European regulatory re-examination.

The European Medicines Agency published grounds for refusal of Daybue regarding efficacy interpretability and long-term benefit evaluation, requiring the sponsor to neutralise these criticisms with additional analyses for a successful resubmission.

A US-only valuation model implies the company's share of the drug is worth $11.17 per share, increasing to $13.09 when incorporating the Japanese market.

Adding a risk-adjusted $8.40 per share for the NNZ-2591 asset yields an overall valuation range between $19.57 and $21.49 should the European approval fail.

The rollout of the new Daybue Stix formulation is expected to drive incremental uptake among treatment-naive patients and prior discontinuations by addressing key administration limitations, the broker notes.